3rd Circ. Parses 'Could' And 'Would' In Lipitor Lawsuit

A Third Circuit panel questioned Tuesday whether drug wholesalers and health plans had offered enough evidence that Pfizer Inc. and Ranbaxy Laboratories Ltd. conspired to delay generic competition for the cholesterol...

Already a subscriber? Click here to view full article